1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters

Showing 1,267 results.

CT - 1036

Establishing T-Cell Engaging Bispecific Antibody Therapy in Community Practice

Daniel Stein

Poster Presenter: Daniel Stein

Thumbnail for Avapritinib Treatment of Patients with Advanced Systemic Mastocytosis: 4-Year Safety, Effect on Bone and First-Line Efficacy Results of the PATHFINDER Clinical Study

MPN - 1037

Avapritinib Treatment of Patients with Advanced Systemic Mastocytosis: 4-Year Safety, Effect on Bone and First-Line Efficacy Results of the PATHFINDER Clinical Study

Michael Deininger

Poster Presenter: Michael Deininger

MPN - 1041

Epetraborole Demonstrates an Exposure-Dependent Effect on Erythropoiesis in Healthy Subjects

George H. Talbot

Poster Presenter: George H. Talbot

$Thumbnail for Efficacy and Safety of Bispecific Antibodies in Relapsed/Refractory T-Cell Lymphoma: A Systematic Review and Single-Arm Meta-Analysis Focusing on Acimtamig (AFM13)$

TCL - 1043

Efficacy and Safety of Bispecific Antibodies in Relapsed/Refractory T-Cell Lymphoma: A Systematic Review and Single-Arm Meta-Analysis Focusing on Acimtamig (AFM13)

Ashil Mulllath

Poster Presenter: Ashil Mulllath

MPN - 1046

Making History With Histiocytes: An Uncommon Presentation of Erdheim Chester Disease

Faizan Azim

Poster Presenter: Faizan Azim

CT - 1048

Early Mortality Following CAR-T Therapy in Hematologic Malignancies: A Population-Level Study

Nanditha Karra

Poster Presenter: Nanditha Karra

Thumbnail for Spliceosome-Targeting Therapies in SF3B1-Mutated Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis of Clinical Efficacy and Safety

MDS - 1049

Spliceosome-Targeting Therapies in SF3B1-Mutated Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis of Clinical Efficacy and Safety

Ashil Mulllath

Poster Presenter: Ashil Mulllath

Thumbnail for ASC4FIRST Week (Wk) 144 Analysis: Continued Superior Efficacy and Favorable Safety of Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed (ND) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

CML - 1050

ASC4FIRST Week (Wk) 144 Analysis: Continued Superior Efficacy and Favorable Safety of Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed (ND) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Ghayas Issa

Poster Presenter: Ghayas Issa

Thumbnail for Clinical Investigators' Selection of Induction and Maintenance Therapy for Patients With Newly Diagnosed Multiple Myeloma Eligible and Ineligible for Transplant

MM - 1051

Clinical Investigators' Selection of Induction and Maintenance Therapy for Patients With Newly Diagnosed Multiple Myeloma Eligible and Ineligible for Transplant

Kevin Pang

Poster Presenter: Kevin Pang